
    
      This study is divided into a 3-week screening period, a 92-week treatment period, and a final
      4-week follow-up period. At baseline patients will be randomized 1:1 into two treatment arms:
      KSI-301 5 mg and aflibercept 2 mg. At Week 52 patients on the aflibercept treatment arm will
      be re-randomized 1:1 into KSI-301 5 mg and aflibercept 2 mg.
    
  